Here, we found that anti-SIRPα treatment could effectively synergize with anti-PD-L1 therapy in treating HCC in vivo without significant changes in body weight or serum indicators of liver and kidney function in mice. This evidence concerns the gene CD274 and hepatocellular carcinoma.